Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →FierceBiotech reported Plexxikon's PLX4032 Phase 1 objective responses in metastatic melanoma — the data that triggered Roche to expand the partnership into…
Retrospective on melanoma therapy development credits the Plexxikon-Roche BRAF program as the inflection point that moved metastatic melanoma from 'nothing…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche expanded its 2006 collaboration with Plexxikon into a second development and commercialization agreement for PLX4032 (vemurafenib), a BRAF inhibitor for metastatic melanoma, in a deal valued at ~$335M.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Plexxikon Inc. (this deal) | 2009 | $335M | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2009 deals · Roche Holding AG deals · Oncology deals